Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390149 | 1.00 | RAB9A (0.40) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL797393 | 0.90 | KMT2A (0.42) | RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL3778464 | 0.89 | POLB (0.44) | RAB9ANPC1KMT2APOLB | |
| SCHEMBL3655590 | 0.89 | POLB (0.44) | RAB9ANPC1KMT2APOLB | |
| SCHEMBL2571964 | 0.86 | RAB9A (0.33) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL19265714 | 0.85 | RAB9A (0.40) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL12522315 | 0.85 | RAB9A (0.40) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL29889256 | 0.83 | RAB9A (0.39) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL26355345 | 0.83 | BRD4 (0.43) | RAB9ANPC1KMT2AMEN1RBP4 | |
| SCHEMBL3160989 | 0.83 | TACR3 (0.36) | RBP4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | RAB9A 4223/4885NPC1 4144/4885KMT2A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.